Thomas Folinsbee
Director/Board Member at CASI PHARMACEUTICALS, INC.
Profile
Thomas Folinsbee is currently the Director of Business Development at Shanghai Alebund Pharmaceuticals Ltd.
and an Independent Director at CASI Pharmaceuticals, Inc. He previously worked as the Director of Corporate Development at 3SBio, Inc. from 2009 to 2019, Director at Hisanaga Seisakusho Co. Ltd.
from 2011 to 2016, and Independent Director at Bison Capital Acquisition Corp.
from 2017 to 2019.
He also served as an Independent Director at Xynomic Pharmaceuticals Holdings, Inc. and Summit Healthcare Acquisition Corp.
Mr. Folinsbee received his undergraduate degree from McGill University in 1990.
Thomas Folinsbee active positions
| Companies | Position | Start |
|---|---|---|
| CASI PHARMACEUTICALS, INC. | Director/Board Member | 2023-03-20 |
| Shanghai Alebund Pharmaceuticals Ltd. | Corporate Officer/Principal | 2018-12-31 |
Former positions of Thomas Folinsbee
| Companies | Position | End |
|---|---|---|
Bison Capital Acquisition Corp.
 Bison Capital Acquisition Corp. Financial ConglomeratesFinance Bison Capital Acquisition Corp. is currently a blank check company, which primarily engages in the acquisition, and engagement in share exchange, share reconstruction and amalgamation with, contractual control arrangement with, purchasing all or substantially all of the assets of an entity. It also plans on engaging in any other similar business combination with one or more entities. The company is headquartered in Beijing, China. | Director/Board Member | 2018-12-31 |
| 3SBIO INC. | Corporate Officer/Principal | 2018-12-31 |
| Hisanaga Seisakusho Co. Ltd. | Director/Board Member | 2015-12-31 |
| SUMT HEAL | Director/Board Member | - |
| XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | Director/Board Member | - |
Training of Thomas Folinsbee
| McGill University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| 3SBIO INC. | Health Technology |
| CASI PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
| Hisanaga Seisakusho Co. Ltd. | |
Bison Capital Acquisition Corp.
Bison Capital Acquisition Corp. Financial ConglomeratesFinance Bison Capital Acquisition Corp. is currently a blank check company, which primarily engages in the acquisition, and engagement in share exchange, share reconstruction and amalgamation with, contractual control arrangement with, purchasing all or substantially all of the assets of an entity. It also plans on engaging in any other similar business combination with one or more entities. The company is headquartered in Beijing, China. | Finance |
Xynomic Pharmaceuticals Holdings, Inc.
 Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China. | Health Technology |
Summit Healthcare Acquisition Corp.
 Summit Healthcare Acquisition Corp. Financial ConglomeratesFinance Summit Healthcare Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The company was founded on December 22, 2020 and is headquartered in Hong Kong. | Finance |
| Shanghai Alebund Pharmaceuticals Ltd. |
- Stock Market
- Insiders
- Thomas Folinsbee
